Apellis Pharmaceuticals, Inc.
APLS
$21.99
$0.743.48%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 132.98% | -10.61% | -3.21% | 45.19% | 78.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 132.98% | -10.61% | -3.21% | 45.19% | 78.29% |
| Cost of Revenue | -24.08% | -20.19% | 15.13% | 31.41% | 19.93% |
| Gross Profit | 389.75% | -0.80% | -31.74% | 66.69% | 771.90% |
| SG&A Expenses | 16.96% | 2.39% | -0.12% | -14.27% | -16.25% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.57% | -7.57% | 6.70% | 3.38% | -1.36% |
| Operating Income | 572.05% | -13.05% | -34.21% | 69.04% | 65.51% |
| Income Before Tax | 480.48% | -11.03% | -38.69% | 58.62% | 59.39% |
| Income Tax Expenses | 1.69% | 308.77% | 100.59% | -79.90% | 154.08% |
| Earnings from Continuing Operations | 475.52% | -11.93% | -38.84% | 58.96% | 59.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 475.52% | -11.93% | -38.84% | 58.96% | 59.04% |
| EBIT | 572.05% | -13.05% | -34.21% | 69.04% | 65.51% |
| EBITDA | 577.38% | -13.26% | -34.45% | 69.40% | 65.73% |
| EPS Basic | 469.01% | -10.07% | -36.08% | 60.05% | 60.34% |
| Normalized Basic EPS | 473.92% | -15.15% | -35.93% | 59.72% | 60.68% |
| EPS Diluted | 461.16% | -10.07% | -36.08% | 60.05% | 60.34% |
| Normalized Diluted EPS | 463.43% | -15.15% | -35.93% | 59.72% | 60.68% |
| Average Basic Shares Outstanding | 1.76% | 1.71% | 2.03% | 2.71% | 3.28% |
| Average Diluted Shares Outstanding | 4.70% | 1.71% | 2.03% | 2.71% | 3.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |